The last time I spoke about Alkermes plc (ALKS), it was with a Seeking Alpha article entitled "Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible." With respect to this article ...

It certainly seems like we’ve entered the era of the Tag Fighter. We’ve got 2XKO repping 2v2 tag action, Marvel Tokon: Fighting Souls planning to introduce the world to a 4v4 fighter later this year, ...

RØDE's impressive NAB 2026 lineup spans a new MEMS microphone platform, a UHF wireless system, an AI podcast app, as well as studio accessories. RØDE arrives at NAB 2026 with an extremely ambitious ...

You can’t sell microphones to the biggest names in showbiz without absorbing the vibe. It’s no wonder Rode owner Peter Freedman has always seemed more ageing rocker than run-of-the-mill Financial ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo ...

Rode's not done releasing trimmed-down versions of its production tools with an eye on budget conscious creators. Today, it's launching Rodecaster Video Core, an all-in-one studio setup which sits ...

The Rode Wireless Micro introduced a feature called Direct Connect, which allows the wireless microphones to pair directly with an iPhone via Bluetooth without the need for a receiver. This same ...

The FDA has started a priority review of Takeda's oveporexton for sleep disorder narcolepsy, setting up a decision in the third quarter of the year. The acceptance of the new drug application (NDA) ...

It’s not often that a pharmaceutical executive discusses a competitor’s success. Alkermes Chief Operating Officer Blair Jackson not only talks about it openly, he cheers it. Alkermes’s scope in ...

Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.

Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its hopes of being first to market in the indication. The trial randomized 93 ...

Posts from this topic will be added to your daily email digest and your homepage feed. The new Rodecaster Video S can switch, mix, and livestream audio and video for $499. The new Rodecaster Video S ...